Form D · Biotechnology

Hopewell Therapeutics, Inc.

Woburn, MA · CIK 0001836562

Offering snapshot reported May 17, 2024 · SEC filing

Reported sold
$7.8M
Offering amount: $10M
Investors reported
8
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
May 19, 2023
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$3.9M$7.8MJun 2, 2023: $3,000,002.00Jun 2, 2023May 17, 2024: $7,800,004.00May 17, 2024

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$3,000,002 → $7,800,004
  • Reported investors1 → 8

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
May 17, 2024Amendment$7,800,004$4,800,002vs Jun 2, 20238SEC filing
Jun 2, 2023Initial$3,000,002No comparison1SEC filing
Feb 2, 2022Initial$7,108,361No comparison4SEC filing
Oct 8, 2021Initial$8,007,235No comparison2SEC filing
Dec 21, 2020Initial$500,000No comparison1SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-483254

Source: Form D, filed May 17, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Thomas Hennessey Director
Xutian Jing Director
Howard Rosen Director
Nan Shen Director
Jake Xia Director
Qiaobing Xu Director, Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
216 West Cummings Park
Woburn, MA, 01801